MicroRNA therapeutics: The emerging anticancer strategies

Recent Patents on Anti-Cancer Drug Discovery

Volumn 9, Issue 3, 2014, Pages 286-296

  Jain, Chakresh K ^a   Gupta, Aman ^a   Dogra, Nidhi ^a   Kumar, Vipul S ^a   Wadhwa, Gulshan ^b   Sharma, Sanjeev K ^a  

^a JAYPEE INSTITUTE OF INFORMATION TECHNOLOGY   (India)

^b DEPARTMENT OF BIOTECHNOLOGY   (India)

Author keywords

Anticancer; Dicer; Drosha; Exportin 5; MicroRNAs; RNA interference; RNA induced silencing complex (RISC); Therapeutics

Indexed keywords

ANTINEOPLASTIC AGENT; MICRORNA;

GENETICS; HUMAN; METABOLISM; NEOPLASMS; ONCOGENE; PATENT; RNA INTERFERENCE;

ANTINEOPLASTIC AGENTS; HUMANS; MICRORNAS; NEOPLASMS; ONCOGENES; PATENTS AS TOPIC; RNA INTERFERENCE;

EID: 84905638483     PISSN: 15748928     EISSN: 22123970     Source Type: Journal    
DOI: 10.2174/1574892809666140307101519     Document Type: Article

References (73)

1. DeSano TJ, Xu L. MicroRNA regulation of cancer stem cells and therapeutic implications. AAPS 2009; 4: 682-692.
2. Nelson PT, Wang WX, Rajeev BW. MicroRNAs (miRNAs) in neurodegenerative diseases. Brain Pathol 2008; 18(1): 130-138.
3. Hansen T, Olsen L, Lindow M, Jakobsen KD, Ullum H, Jonsson E, et al. Brain expressed microRNAs implicated in schizophrenia etiology. Plos One 2007; 9: 873-880.
4. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 2007; 21: 1025-1030.
5. Garzon R, Marcucci G, Croce MC. Targeting microRNAs in can- cer: Rationale, strategies and challenges. Nature 2010; 9: 775-789.
6. Calin AG, Croce MC. MicroRNA signatures in human cancers. Nature 2006; 6: 857-866.
7. Neelakandan K, Babu P, Nair S. Emerging roles for modulation of microRNA signatures in cancer chemoprevention. Curr Cancer Drug Targets 2012; 12(6): 716-740.
8. Das DK, Mukhopadhyay P. MicroRNA signatures of stem cells. Exp Clin Cardiol 2011; 16(3): 13-16.
9. Lennox KA, Behlke MA. Chemical modification and design of anti-miRNA oligonucleotides. Gene Therapy 2011; 18: 1111-1120.
10. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
11. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yenda-Muri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. PNAS 2004; 101(9): 2999-3004.
12. Wang Z. MicroRNA: A matter of life or death. WJBC 2010; 1(4): 41-54.
13. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: MicroRNA biogenesis pathways and their regulation. Nat Cell Biol 2009; 11(3): 228-234.
14. Wu H, Ye C, Ramirez D, Manjunath N. Alternative processing of primary microRNA transcripts by Drosha generates 59 end variation of mature microRNA. Plos One 2009; 04: 1-12.
15. Liu Z, Sall A, Yang D. MicroRNA: An emerging therapeutic target and intervention tool. Int J Mol Sci 2008; 9: 978-999.
16. Kim VN, Nam JW. Genomics of microRNA. Trends Genet 2006; 22(3): 165-73.
17. Prochazka IS, Durmus S, Kroesen BJ, Berg AD. MicroRNAs, macrocontrol: Regulation of miRNA processing. RNA 2010; 16:1087-1095.
18. Davis-Dusenbery BN, Hata A. Mechanisms of control of microRNA biogenesis. J. Biochem 2010; 148(4): 381-392.
19. Westholm JO, Lai EC. Mirtrons: MicroRNA biogenesis via splicing. Biochimie 2011; 93: 1897-1904.
20. Feng Y, Zhang X, Graves P, Zeng Y. A comprehensive analyzis of precursor microRNA cleavage by human Dicer. RNA 2012; 18: 2083-2092.
21. Gironella M, Seux M, Xie MJ, Cano C, Tomasini R, Gommeaux J, et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. PNAS 2007; 104(41): 16170-16175.
22. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Molecular Cell 2007; 26: 745-752.
23. Wang X, Zhao X, Gao P, Wu M. c-Myc modulates microRNA processing via the transcriptional regulation of Drosha. Scientific Reports 2013; 3: 1-7.
24. Bauersachs J, Thum T. Biogenesis and regulation of cardiovascular MicroRNAs. Circulation Res 2011: 109: 334-347.
25. Castellanoa L, Giamasa G, Jacoba J, Coombesa RC, Lucchesib W, Thiruchelvama P, et al. The estrogen receptor-a-induced microRNA signature regulates itself and its transcriptional response. PNAS 2009; 106(27): 15732-15737.
26. Trabucchi M, Briata P, Mayoral MG, Haase AD, Filipowicz W, Ramos A, et al. The RNA-binding protein KSRP promotes the biogenesis of a subset of miRNAs. Nature 2009; 459(7249): 1010-1014.
27. Melo SA, Moutinho C, Ropero S, Calin GA, Rossi S, Spizzo R, et al. A genetic defect in exportin-5 traps precursor MicroRNAs in the nucleus of cancer cells. Cancer Cell 2010; 18: 303-15.
28. Asangani IA, Rasheed SAK, Nikolova DA, Leupold JH, Colburn NH, Post S, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, in-travasation and metastasis in colorectal cancer. Oncogene 2008; 27: 2128-21236.
29. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, et al. A polycistronic MicroRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005; 65: 9628-9632.
30. Nagel R, Sage LC, Diosdado B, Waal DM, Vrielink OJ, Bolijn A, et al. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res 2008; 68: 5795-5802.
31. Gupta A, Verma A, Mishra AK, Wadhwa G, Sharma KS, Jain KC. The Wnt pathway: Emerging anticancer strategies. Recent Pat En-docr Metab Immune Drug Discov 2013; 7(2): 138-147.
32. Han CY, Park CY, Bhagat G, Zhang J, Wang Y, Fan BJ, et al. MicroRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia. JEM 2010; 207(3): 475-489.
33. Garzia L, Andolfo I, Cusanelli E, Marino N, Petrosino G, Martino DD, et al. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. Plos One 2009; 4: 1-14.
34. Yu F, Yao H, Zhu P, Zhang X, Pan O, Gong C, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007; 137: 1109-1123.
35. Ji Q, Hao X, Meng Y, Zhang M, DeSano J, Fan D, et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008; 8: 266-278.
36. Godlewski J, Nowicki MO, Bronisz A, Williams S, Otsuki A, Nuovo G, et al. Targeting of the Bmi-1 oncogene/stem cell renewal factor by MicroRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res 2008; 68: 9125-9130.
37. Huibregtse, S.B. MicroRNAs differentially expressed in cervical cancer and uses thereof. US20090186348 (2009).
38. Mambo, E. MicroRNA markers for recurrence of colorectal cancer. US20090233297 (2009).
39. Bentwich, I. Prostate cancer-related nucleic acids. US7642348 (2010).
40. Bentwich, I. MicroRNAs and uses thereof. US7709616 (2010).
41. Croce, C.M. Diagnosis and treatment of cancers with microRNA located in or near cancer. US20100234241 (2010).
42. Brown, D. Methods and compositions involving microRNA. US7888010 (2011).
43. Croce, C.M. MicroRNA signatures in human ovarian cancer. US20100249213 (2010).
44. Schmittgen, T.D. MicroRNA expression profile associated with pancreatic cancer. US20100286232 (2010).
45. Watson, D.K. MicroRNA diagnostics for cancer. US20100297627 (2010).
46. Croce, C.M. MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer. US7943318 (2011).
47. Dmitrovsky, E. MicroRNA biomarkers for human breast and lung cancer. US7955848 (2011).
48. Harris, C.C. Inflammatory genes and microRNA-21 as biomarkers for colon cancer prognosis. US20110183859 (2011).
49. Taylor, D.D. Cancer-derived microvesicle-associated microRNA as a diagnostic marker. US8216784 (2012).
50. Zhang, L. MicroRNA biomarker in cancer. US20120015049 (2012).
51. Goel, A. MicroRNAs (miRNA) as biomarkers for the identification of familial and non- familial colorectal cancer. US20120088687 (2012).
52. Keller, A. MiRNA in the diagnosis of ovarian cancer. US20120309645 (2010).
53. Ju, J. MicroRNA as biomarker in cancer. US8343719 (2013).
54. United States Patent and Trademark Office website. Available at: http://www.uspto.gov/. (Accessed on: August 12, 2013).
55. Espacenet website. Available at: http://ep.espacenet.com/. (Accessed on: August 12, 2013).
56. Fan, J., Zhou, J., Dai, Z., Yu, L., Hu, J., Wang, Z. Marker consisting of plasma microRNA and new method for diagnosis of hepato-cellular carcinoma. EP2181332 (2013).
57. Taylor, D.D., Taylor, G.C. Exosome-associated microRNA as a diagnostic marker. EP2181332 (2013).
58. Adai, A., Schwarzbach, S.S., Andruss, B., Hahn, A.S. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic. WO2013040251 (2013).
59. Adai, A.T., Szafranska-Schwarzbach, A.E., Andruss, B.F., Maitra, A., Matthaei, H., Wylie, D. Methods and compositions involving miRNA expression levels for distinguishing pancreatic cysts. WO2013063519 (2013).
60. Lieberman, J. Let-7 microRNA and mimetics thereof as therapeutics for cancer. US20100310583 (2010).
61. Croce, C.M. MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of solid cancer. US8148069 (2012).
62. Nana-Sinkam, S. P. MicroRNA expression profiling and targeting in peripheral blood in lung cancer. US20100323357 (2010).
63. Mo, Y.Y. MicroRNA-mediated regulation of ubc9 expression in cancer cells. EP2358372 (2012).
64. Park, J.B. Composition containing microRNA-21 inhibitor for enhancing radiation sensitivity. US20110021601 (2011).
65. Park, J.B. Anti-cancer composition comprising microRNA molecules. US20110124712 (2011).
66. Obad, S. MicroRNAs. US8288356 (2012).
67. Zhan, Q. Use of two microRNA moleculars in lung cancer prognosis and medicine preparation. US20120220644 (2012).
68. Gunaratne, P.H. MicroRNA-29a, b,c as a tumor suppressor and sensitizing agent for chemotherapy. US20120251619 (2012).
69. Gunaratne, P.H. MicroRNA-140-5P as a tumor suppressor and sensitizing agent for chemotherapy. US20120269883 (2012).
70. Shen, J., Kelnar, K., Shelton, J., Brown, D., Campochiaro, P. Compositions and methods related to miRNA modulation of neovascu-larization or angiogenesis. US20130065951 (2013).
71. Tsou, P.A., Tsai, C.W., Hsu, S.C. Compositions and method for detecting and treating abnormal liver homeostasis and hepatocar-cinogenesis. US20130142861 (2013).
72. Ochiya, T., Fujiwara, T. MicroRNA-based methods and assays for osteosarcoma. WO2013034989 (2013).
73. Lamond, I.A., Ono, M., Ono, K. Targeting of miRNA precursors. WO2013054113 (2013).